Fifty CEOs and how they reached the chair. Ten decisions before the books close on 2026. An independent benchmark of twelve bioeconomies. Dispatches from Bangkok, San Diego and Taipei. And five country reports that read entire markets, one at a time.
Every publication reaches a point where reporting the news is no longer enough. This year, BioSpectrum Asia set itself a harder brief: not just to tell you what happened across Asia-Pacific's life sciences, but to explain what it means, where it leads, and what a leadership team should do about it.
The pages collected here are the result. The CEO Handbook stepped away from the comfort of a ranking to ask how fifty chief executives actually reached the chair. Our Q4 whitepaper distilled a planning season into ten decisions no leadership team can defer. The APAC Bioeconomy Index gave the region its first independent, twelve-market read on capability and resilience. Our reporters filed from the convention floors of Bangkok, San Diego and Taipei, one leader at a time. And the Country Report Series treated each market as a story worth telling whole: Singapore learning to invent, Taiwan fusing chips with cells, Thailand turning a medical hub into a medicine maker, Korea plotting its next act, Japan confronting its queue.
All of it is free to read and download. That is deliberate. The conversations this region needs are better held in the open. I hope you find something here that changes one of yours.
This Career Spotlight edition departs from the format of an annual ranking. Rather than ordering leaders by company size or market capitalisation, it examines how each of them actually reached the chair, revealing seven distinct career routes and the defining moves that shaped every journey.
Read it for the patterns: the operators who rose through plants, the scientists who learned the balance sheet, the dealmakers, the founders, and the moves each of them made when the top job came into view.
Read the handbookThe critical calls on tariffs, regulation, out-licensing, AI, capacity, capital and talent that could define APAC life sciences performance in 2027. One planning window, ten decisions that will not wait.
Benchmarking the capability and commercial resilience of Asia-Pacific's bioeconomy: one independent read on where the region leads, where it lags, and what to do next.
APAC is building biopharma capacity faster than the workforce to run it. This report maps the roles employers cannot fill, why the pipeline fails, and how the leaders are closing the gap.
Read the report, then score your own organisation against the index.
The global biotech floor, heard one leader at a time. Full coverage from the halls in Bangkok, as the region's laboratory and life sciences community set out its next chapter.
Read the coverageBioSpectrum Asia set up its field desk on the convention floor. Across four days, we sat down with the founders, scientists and investors steering biotech's next decade: from AI antibody discovery in Seoul to personalised cancer vaccines and the supply chains behind advanced therapies.
Read the dispatchesTwelve stories from BIO Asia-Taiwan 2026, reported from inside the halls at TaiNEX. Not a summary of the programme. An argument about where this industry is going, filed from the place it is going to.
Read the event reportTwo decades as Asia's biopharma factory floor. Now, with a unicorn on the board and a home-grown gene therapy heading to the clinic, can Singapore learn to invent, not just manufacture?
Taiwan makes the silicon the world's AI runs on. Now it wants the same edge in medicine, fusing semiconductors, AI and one of the planet's largest genomic cohorts. Can compute become cures?
Thailand treats the region. It does not, for the most part, make what it treats the region with. Can healthcare demand finally pull an industry behind it?
The country that makes the world's biologics is trying to learn to invent its own. Inside Korea's bid to climb from factory to founder.
Japan approved the world's first iPS cell therapies in March 2026 and owns one of oncology's most valuable franchises. It is also a country where 86 Western-approved medicines had not begun development at all.
The Country Report Series continues across Asia-Pacific's major life sciences markets. New editions publish through 2026 and 2027.
Conversations with the founders, scientists and executives shaping Asia-Pacific's life sciences, from the lab bench to the boardroom.
BioSpectrum Asia was on the floor as official media partner. Watch the highlight film, then browse the moments that mattered: the sessions, the speakers, the conversations between them, captured frame by frame.
View the photo gallery